Biotechnology startup Pandorum Technologies has secured $18 million in a Series B funding round led by Protons Corporate, with participation from investors including Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family. The funding was completed in two phases, finalized between November and December, strengthening the company’s capital base for the next phase of growth.
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum Technologies operates in the regenerative medicine sector, developing programmable tissue regeneration solutions based on exosome-driven technologies. The company maintains operations across both India and the United States while adopting a globally distributed manufacturing approach.
To support production and global supply, Pandorum has partnered with AGC Biologics for manufacturing services in the U.S. and Europe, and with Nucelion Therapeutics, part of the Bharat Biotech group for distribution across the Asia-Pacific region. The company is also exploring additional partnerships in the Middle East to further expand its presence.
